Cooperative Agreement UG3DE033354

Award Date 6/1/25
Completion Date 5/31/26
Dollars Obligated $604K
Federal Grant Program
93.121
Assistance Type
Cooperative Agreement
Place of Performance
North Carolina, USA
Similar Awards
The National Institute of Dental and Craniofacial Research (NIDCR) has awarded a 5-year, $2,854,699 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) program to the University of Southern California (USC). The grant will fund research to create a comprehensive molecular, cellular, and innervation map of the temporomandibular joint (TMJ) under healthy and osteoarthritis conditions. The goal is to identify new therapeutic targets for mitigating TMJ osteoarthritis and...
This $2,145,920.63 Cooperative Agreement award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports a research project at Thomas Jefferson University (Sidney Kimmel Medical College) to utilize single cell RNA sequencing to identify and classify cell populations and gene expression in temporomandibular joint (TMJ) synovial fluid from healthy and symptomatic TMJ disorder patients. The central...
This federal Cooperative Agreement award, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports a multi-year research project focused on understanding the molecular and cellular mechanisms underlying temporomandibular joint (TMJ) disorders. The $587,428 award, effective September 17, 2024 through August 31, 2026, will be implemented by the University of California, Los Angeles (UCLA) to identify...
This $168,228 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), aims to evaluate the feasibility and potential efficacy of a novel local anesthetic technique called the Temporo-Masseteric Nerve Block (TMNB) in reducing post-surgical pain and improving jaw function following impacted third molar (wisdom tooth) extractions. The principal investigator, Dr. Subramanian, will...
This $2,743,242 Project Grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will fund research to understand the factors contributing to variability in the analgesic response to ibuprofen following third molar extraction. The work aims to identify biomarkers predictive of a patient's need for opioid rescue medication in addition to non-steroidal anti-inflammatory drugs (NSAIDs) to achieve...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $312,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the Regents of the University of Michigan Office of Research and Sponsored Projects to establish the Michigan Collaborative Hub for TMD Patient-Centric Research (MICH T PCR). The goal of the award is to transform the treatment of temporomandibular disorders (TMDs) through the translation of clinically-relevant innovations. The...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $245,504 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to the University of North Carolina at Chapel Hill (UNC-CH) to develop new transgenic mouse models and conduct pre-clinical evaluation of a novel small molecule inhibitor targeting the stress-specific function of the Replication Protein A (RPA) complex in oral squamous cell carcinoma (OSCC) treatment. The research aims to explore the potential...
This $376,310 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a 16-week randomized controlled trial to evaluate the efficacy and biochemical mechanisms of a dietary intervention targeting omega-3 and omega-6 fatty acids for the treatment of chronic low back pain. The award will fund activities to update the dietary...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $222,500 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Children's Hospital of Philadelphia (CHOP) to study the pathogenic mechanisms of temporomandibular joint (TMJ) osteophyte formation. The research aims to test the hypothesis that a steep local loss of heparan sulfate triggers osteophyte formation in TMJ osteoarthritis. The grant will fund experiments to determine if...
This federal Project Grant award, identified as R21DE033502, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The $250,500 award, with a performance period from August 1, 2024 to July 31, 2026, supports the development of "Face-Forward-Web", a novel web-based program targeting pain-related outcomes among patients with heterogeneous chronic orofacial pain conditions. The key...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $603,502 Cooperative Agreement (UG3/UH3 grant type) to the University of North Carolina at Chapel Hill (UNC-CH) under the Oral Diseases and Disorders Research program (CFDA 93.121). The purpose of this 12-month award is to conduct a Phase 2B, proof-of-concept, randomized, placebo-controlled clinical trial to evaluate the safety and analgesic efficacy of a marine oil supplement containing omega-3 fatty acid derivatives in adults with chronic temporomandibular pain. The study aims to quantify safety, measure changes in pain intensity, and assess impacts on hyperalgesia, psychosocial distress, and sleep. The project will utilize advanced analytical methods to profile targeted bioactive lipid mediators and correlate biochemical changes with clinical outcomes. If successful, this research could lead to a novel therapeutic approach for chronic temporomandibular pain that resolves inflammation and reduces pain, sleep disturbance, and psychological distress.

Generated 6/17/25, 4:07 AM